<?xml version="1.0" encoding="UTF-8"?>
<p>The Ebola virus disease (EVD) outbreak that began in the Kivu province of the Democratic Republic of the Congo (DRC) in 2018 is now the second largest in history [
 <xref rid="B1-vaccines-08-00038" ref-type="bibr">1</xref>]. It is also the largest and most deadly of the ten Ebola outbreaks to occur in DRC [
 <xref rid="B2-vaccines-08-00038" ref-type="bibr">2</xref>], the country where Ebola was first identified during the 1976 Yambuku outbreak [
 <xref rid="B3-vaccines-08-00038" ref-type="bibr">3</xref>]. Throughout multiple outbreaks of EVD, the infection has had a significant case fatality rate (CFR) among all persons who became infected, but historically the mortality has been especially high among pregnant women, fetuses and infants (less than 1 year of age) [
 <xref rid="B4-vaccines-08-00038" ref-type="bibr">4</xref>,
 <xref rid="B5-vaccines-08-00038" ref-type="bibr">5</xref>,
 <xref rid="B6-vaccines-08-00038" ref-type="bibr">6</xref>,
 <xref rid="B7-vaccines-08-00038" ref-type="bibr">7</xref>]. Prior to the West African Ebola epidemic which began in Guinea in December 2013, it was generally believed that EVD occurring in a pregnant woman was close to being non-survivable. Previous Ebola outbreaks had demonstrated that from 75 to greater than 90 percent of infected pregnant women had died as a result of EVD [
 <xref rid="B4-vaccines-08-00038" ref-type="bibr">4</xref>,
 <xref rid="B6-vaccines-08-00038" ref-type="bibr">6</xref>,
 <xref rid="B8-vaccines-08-00038" ref-type="bibr">8</xref>,
 <xref rid="B9-vaccines-08-00038" ref-type="bibr">9</xref>].
</p>
